---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002912"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:28:04.933627+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Coherus Q4 net loss $58.9M, revenue $45.4M; cuts 60 jobs; CSO resigns; UDENYCA AI approved

## Summary
- Q4 net revenue $45.4M (down from $73.4M YoY); net loss $58.9M ($0.76 per share) vs $45.7M loss in Q4 2021.
- Full year 2022 net revenue $211.0M (down from $326.6M); net loss $291.8M ($3.76 per share).
- Workforce reduction of ~60 employees (~20%) to focus on strategic priorities; expects $3.4M restructuring charges.
- CSO Vladimir Vexler resigned effective March 10, 2023 (or later at his option), not due to disagreement.
- FDA approved UDENYCA autoinjector; toripalimab manufacturing inspection planned for Q2 2023; 2023 opex guidance $315-335M.

## SEC filing metadata
- accession: 0001558370-23-002912
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/chrs-20230302x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002912
- JSON: https://secwatch.observer/filing/0001558370-23-002912.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002912.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).
  - Period: fourth quarter and full year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On March 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm
- Executive change
  Vladimir Vexler resigned as Chief Scientific Officer at Coherus Oncology, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On March 2, 2023, Vladimir Vexler, Ph.D., resigned from his role as Chief Scientific Officer of the Company, effective March 10, 2023, unless the effective date is extended to March 31, 2023 at Dr. Vexler’s option.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm
- Restructurings & Charges
  Coherus Oncology, Inc. announced a restructuring with charges of approximately $3.4 million (approximately 60 full-time and part-time employees).
  - Type: restructuring
  - Charge: approximately $3.4 million
  - Headcount: approximately 60 full-time and part-time employees
  source text: On March 3, 2023, the Company committed to a plan to reduce its workforce (the “Plan”) by approximately 20% to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The Company initiated a reduction in force impacting approximately 60 full-time and part-time employees effective March 10, 2023 for most employees. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.4 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023002912/0001558370-23-002912-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.